Neurocrine Biosciences Inc
$ 131.15
0.15%
25 Feb - close price
- Market Cap 13,162,668,000 USD
- Current Price $ 131.15
- High / Low $ 132.25 / 130.02
- Stock P/E 28.02
- Book Value 32.50
- EPS 4.68
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.10 %
- ROE 0.16 %
- 52 Week High 160.18
- 52 Week Low 84.23
About
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric diseases and disorders in the United States. The company is headquartered in San Diego, California.
Analyst Target Price
$177.11
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-11 | 2025-10-30 | 2025-07-30 | 2025-05-05 | 2025-02-06 | 2024-10-30 | 2024-08-01 | 2024-05-01 | 2024-02-07 | 2023-10-31 | 2023-08-01 | 2023-05-03 |
| Reported EPS | 1.88 | 2.17 | 1.65 | 0.7 | 1.69 | 1.81 | 0.63 | 0.42 | 1.44 | 0.82 | 0.95 | -0.79 |
| Estimated EPS | 1.86 | 2.09 | 1.5 | 1.09 | 1.93 | 1.82 | 1.05 | 1.01 | 1.15 | 0.97 | 0.78 | 0.13 |
| Surprise | 0.02 | 0.08 | 0.15 | -0.39 | -0.24 | -0.01 | -0.42 | -0.59 | 0.29 | -0.15 | 0.17 | -0.92 |
| Surprise Percentage | 1.0753% | 3.8278% | 10% | -35.7798% | -12.4352% | -0.5495% | -40% | -58.4158% | 25.2174% | -15.4639% | 21.7949% | -707.6923% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.42 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NBIX
2026-02-26 13:52:21
Neurocrine Biosciences, a small-cap pharmaceutical company, has seen a revision in its stock evaluation, boasting strong financial metrics like a P/E ratio of 36, a price-to-book value of 5.20, and a ROCE of 28.21%. Despite a year-to-date return of -7.53%, its one-year return of 13.16% has outperformed the S&P 500, indicating resilience in a competitive market as it holds a more favorable valuation profile compared to some peers.
2026-02-26 11:52:21
Fox Run Management L.L.C. recently purchased 9,887 shares of Neurocrine Biosciences (NASDAQ:NBIX) valued at approximately $1.388 million, making them a new institutional investor in the company, which is now 92.59% institutionally owned. Despite this, there has been significant insider selling, with CEO Kyle Gano and Director Leslie V. Norwalk collectively selling shares worth over $5.5 million. Analysts maintain a "Moderate Buy" rating with a consensus target price of $175.05 for Neurocrine Biosciences, despite the company missing its recent EPS estimate but exceeding revenue expectations.
2026-02-26 00:52:21
Neurocrine Biosciences reported strong Q4 2025 results with revenue of US$805.5 million and net income of US$153.7 million, with full-year revenue reaching US$2.86 billion. The company provided 2026 guidance for INGREZZA net product sales between US$2.70 billion and US$2.80 billion, reinforcing its role as a primary earnings driver. This performance strengthens the existing investment narrative for NBIX, supported by share repurchases, although risks related to INGREZZA pricing and market concentration remain.
2026-02-25 16:53:11
In Q4 2025, Neurocrine Biosciences reported strong financial results with increased revenue and net income, alongside positive 2026 guidance for its key drug, INGREZZA. These results reinforce the company's investment narrative, which heavily relies on INGREZZA as the primary growth driver and is supported by ongoing share repurchases. However, the article highlights the continued risk of pricing pressure and product concentration for NBIX, urging investors to consider these factors against the positive performance.
2026-02-25 00:52:21
Neurocrine Biosciences Inc (NASDAQ:NBIX) exhibits strong fundamentals, including high expansion measures, robust earnings and margins, and firm financial soundness with no debt. Despite a middle-range Price Rating, its valuation appears somewhat low compared to biotech peers. The stock's chart pattern suggests a possible upward move, having consolidated sideways above a clear support zone, making it a compelling candidate for growth-focused investors.
2026-02-24 23:53:12
Wolfe Research has initiated coverage of Neurocrine Biosciences (NBIX) with an Outperform recommendation, setting an average one-year price target of $182.16, suggesting a 41.89% upside. Despite a projected 13.55% decrease in annual revenue to $2,473MM, the company's non-GAAP EPS is expected to be 16.08. Institutional ownership remains significant, with key holders like Dodge & Cox and JPMorgan Chase adjusting their positions.
